Is Blackrock Going "Activist" With AstraZeneca?

Is the activist strategy spreading to traditional establishment investors such as BlackRock, Inc. (NYSE:BLK)? Blackrock communicating its desires to AstraZeneca BlackRock, Inc. (NYSE:BLK), the epitome of establishment institutional investing, may be finding its voice.  The New York Times is reporting that BlackRock, AstraZeneca plc (ADR) (NYSE:AZN) (LON:AZN)’s largest shareholder, is making public its desire for the drug maker to renew talks with Pfizer Inc. (NYSE:PFE) about a potential deal. Typically conservative institutional investors seldom, if ever, speak against management decisions in the companies in which they were invested. BlackRock, Inc. (NYSE:BLK)’s, which is an 8% owner in AstraZeneca plc (ADR)…